Skip to main content
SpringerLink
Log in

Bridging therapy for early surgery in patients on dual antiplatelet therapy after drug-eluting stent implantation

  • Original Article
  • Published:
Netherlands Heart Journal Aims and scope Submit manuscript

Abstract

Objectives

To evaluate stent-related adverse cardiac events and bleeding complications within 30 days after surgical procedures in patients with recent drug-eluting stent (DES) implantation, in whom a bridging protocol was used.

Methods

In our centre a bridging protocol is used in patients scheduled for cardiac or non-cardiac surgery within 6 months after PCI with DES implantation. Clopidogrel and in some cases also acetylsalicylic acid is discontinued 5 days prior to the planned intervention and patients are admitted 2 to 3 days before the intervention for tirofiban infusion. This is discontinued 4 h before intervention. Close postoperative monitoring is performed and double antiplatelet therapy is restarted as soon as possible. Thirty-six consecutive patients were included in the protocol, 15 receiving coronary artery bypass graft and 21 non-cardiac interventions. Thrombotic and bleeding complications were studied for up to 30 days after the bridged procedure.

Results

No incidences of stent thrombosis or other adverse cardiac events (mortality, myocardial infarction) were seen in up to 30 days of follow-up. However, 6 bleeding events were reported of which 5 required a blood transfusion.

Conclusion

Our bridging protocol in patients requiring surgery after recent PCI with DES seems adequate to prevent stent thrombosis in this high-risk group. The bleeding risk is not insignificant but in our patient group controllable without major late sequelae. Larger studies should be performed to establish safety and efficacy in order to develop guidelines for these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sousa JE, Costa MA, Abizaid AC, et al. Four year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus eluting stents. Circulation. 2005;111:2326–9.

    Article  PubMed  CAS  Google Scholar 

  2. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–80.

    Article  PubMed  CAS  Google Scholar 

  3. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–23.

    Article  PubMed  CAS  Google Scholar 

  4. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221–31.

    Article  PubMed  CAS  Google Scholar 

  5. Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the “real world”: the Rapamycin-eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation. 2004;109:190–5.

    Article  PubMed  CAS  Google Scholar 

  6. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364(9444):1519–21.

    Article  PubMed  CAS  Google Scholar 

  7. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126–30.

    Article  PubMed  CAS  Google Scholar 

  8. Rodriguez AE, Mieres J, Fernandez-Pereira C, et al. Coronary stent thrombosis in the current drug-eluting stent era: insights from the ERACI III trial. J Am Coll Cardiol. 2006;47:2057.

    Article  Google Scholar 

  9. Ong AT, McFadden EP, Regar E, et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol. 2005;45:2088–92.

    Article  PubMed  CAS  Google Scholar 

  10. Pfisterer M, Brunner-La H, Rocca P, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48:2584–91.

    Article  PubMed  CAS  Google Scholar 

  11. Smith SC, Feldman TE, Hershfeld Jr JW, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention–summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI writing committee to update the 2001 guidelines for percutaneous coronary intervention). J Am Coll Cardiol. 2006;47:216–35.

    Article  PubMed  Google Scholar 

  12. Mayor S. Drug-eluting stents are safe for licensed indications, FDA says. BMJ. 2006;333:1235.

    Article  PubMed  Google Scholar 

  13. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. 2005;26:804–47.

    Article  PubMed  Google Scholar 

  14. Vicenzi MN, Meislitzer T, Halaj HM, et al. Coronary artery stenting and non-cardiac surgery—a prospective outcome study. Br J Anaesth. 2006;96:686–93.

    Article  PubMed  CAS  Google Scholar 

  15. Kaluza GL, Joseph J, Lee JR, et al. Catastrophic outcomes of non-cardiac surgery soon after coronary stenting. J Am Coll Cardiol. 2000;35:1288–94.

    Article  PubMed  CAS  Google Scholar 

  16. Spahn DR, Howell SJ, Delabays A, et al. Coronary stents and perioperative anti-platelet regimen: dilemma of bleeding and stent thrombosis. Br J Anaesth. 2006;96:675–7.

    Article  PubMed  CAS  Google Scholar 

  17. Burger W, Chemnitius JM, Kneissl GD, et al. Low-dose aspirin for secondary cardiovascular prevention—cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation: a review and meta-analysis. J Intern Med. 2005;257:399–414.

    Article  PubMed  CAS  Google Scholar 

  18. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ. 2002;324:71–86.

    Article  Google Scholar 

  19. Davies BR. Combined aspirin and clopidogrel in cataract surgical patients: a new risk factor for ocular haemorrhage? Br J Ophthalmol. 2004;88:1226–7.

    Article  PubMed  CAS  Google Scholar 

  20. Ernst A, Eberhardt R, Wahidi M, et al. Effect of routine clopidogrel use on bleeding complications after transbronchial biopsy in humans. Chest. 2006;129:734–7.

    Article  PubMed  Google Scholar 

  21. Harder S, Klinkhardt U, Alvarez JM. Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinetics. 2004;43:963–81.

    Article  CAS  Google Scholar 

  22. Weber AA, Braun M, Hohfeld T, et al. Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. Br J Clin Pharmacol. 2001;52:333–6.

    Article  PubMed  CAS  Google Scholar 

  23. Albaladejo P, Marret E, Piriou V. Perioperative management of antiplatelet agents in patients with coronary stents: recommendations of a French Task Force. Br J Anaest. 2006;97(4):580–5.

    Article  CAS  Google Scholar 

  24. Emmanouil SB, Subhash B, Berger PB. Perioperative management of patients with coronary stents. J Am Coll Cardiol. 2007;49:2145–50.

    Article  Google Scholar 

  25. Broad L, Lee T, Conroy MB, et al. Successful management of patients with a drug-eluting coronary stent presenting for elective, non-cardica surgery. Br J Anaest. 2007;98(1):19–22.

    CAS  Google Scholar 

  26. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 2001;119:39S–63S.

    Article  PubMed  CAS  Google Scholar 

  27. Genoni M, Zeller D, Bertel O, et al. Tirofiban therapy does not increase the risk of hemorrhage after emergency coronary surgery. J Thorac Cardiovasc Surg. 2001;122:630–2.

    Article  PubMed  CAS  Google Scholar 

  28. Schouten O, van Domburg RT, Bax JJ, et al. Non-cardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. J Am Coll Cardiol. 2007;49:122–4.

    Article  PubMed  Google Scholar 

  29. Compton PA, Zankar AA, Adesanya AO, et al. Risks of non-cardiac surgery after coronary drug-eluting stent implantation. Am J Cardiol. 2006;98:1212–3.

    Article  PubMed  Google Scholar 

  30. Broad L, Lee T, Conroy M, et al. Successful management of patients with a drug-eluting coronary stent presenting for elective, non-cardiac surgery. Br J Anaesth. 2007;98:19–22.

    Article  PubMed  CAS  Google Scholar 

  31. Bizzarri F, Scolletta S, Tucci E, et al. Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2001;122:1181–5.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Medical Center Leeuwarden, Henri Dunantweg 3, 8932 BA, Leeuwarden, the Netherlands

    E. G. Marcos & S. H. Hofma

  2. Department of Cardiology, Isala Hospital, Zwolle, the Netherlands

    A. C. Da Fonseca

Authors
  1. E. G. Marcos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. C. Da Fonseca
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. H. Hofma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. G. Marcos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marcos, E.G., Da Fonseca, A.C. & Hofma, S.H. Bridging therapy for early surgery in patients on dual antiplatelet therapy after drug-eluting stent implantation. Neth Heart J 19, 412–417 (2011). https://doi.org/10.1007/s12471-011-0197-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12471-011-0197-y

Keywords

Search

Navigation